Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Reuters reported that Takeda Pharmaceutical Company Limited (NYSE:TAK) and US biotechnology company Nabla Bio signed a major research partnership. The partnership is focused on deepening the use of AI to accelerate drug delivery.
This partnership builds on an earlier collaboration, which was launched between the two companies in 2022. As part of this partnership, Nabla will use its proprietary AI platform called the Joint Atomic Model (JAM) to design protein-based treatments for Takeda Pharmaceutical Company Limited’s (NYSE:TAK) early-stage pipeline.
As per the report, the company will pay an upfront payment in double-digit millions to Nabla, whereas Nabla would also be eligible for success-based payments worth more than $1 billion. The CEO of Nabla, Surge Biswas, noted that JAM would respond to molecular queries similar to how ChatGPT answers questions.
Takeda Pharmaceutical Company Limited (NYSE:TAK) is a Japanese biotech company that specializes in the research, development, and sale of pharmaceuticals. The company focuses on gastrointestinal, rare, immune, cancer, and neuropsychiatric diseases.
While we acknowledge the potential of TAK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
-1024x768.jpg "Red Snapper Used as Cudgel by Fed Judge")
